stockrow
Friday 6 November 2026
Export STVN’s income statement to Excel — free account
Stevanato Group S.p.A.
STVN Healthcare Medical Instruments & Supplies
Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024.
- Revenue
- +5.91%
- EPS
- +17.5%
- Free cash flow
- +4,089.9%
- Total debt
- +2.85%
Quarter to September 2026, against a year earlier
13.51
0.30
+2.27%
Follow STVN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
5 | 6 | 6 | 5 |
| 9.88% | 9.93% | 9.21% | 9.22% | ||
| 5.86% | 5.96% | 5.46% | 5.50% | ||
ROIC |
6.84% | 6.71% | 6.56% | 6.71% | |
Return on Tangible Assets |
7.77% | 7.72% | 7.33% | 7.42% | |
Average Days of Receivables |
108.69 | 101.93 | 107.02 | 107.53 | |
Free Cash Flow per Share |
0.05 | (0.04) | (0.13) | (0.03) | |
Free Cash Flow |
14.60 | (10.20) | (34.67) | (8.79) | |
Capital Expenditures |
(309.07) | (317.04) | (318.84) | (297.97) | |
| Other line items | |||||
Cash ROIC |
0.61% | (0.41%) | (1.43%) | (0.35%) | |
Accounts Receivable Turnover |
3.37 | 3.89 | 3.73 | 3.69 | |
Accounts Payable Turnover |
3.48 | 3.65 | 3.66 | 3.89 | |
Inventory Turnover |
3.35 | 3.19 | 3.01 | 3.07 | |
Average Days of Payables |
114.09 | 109.91 | 107.52 | 100.15 | |
Days of Inventory on Hand |
116.23 | 127.20 | 129.82 | 123.57 | |
Tax Rate |
(0.26) | (0.27) | (0.30) | (0.31) | |
Research and Development Expense of Revenue |
2.14% | 2.11% | 2.09% | 1.93% | |
Selling, General and Administrative Expense of Revenue |
10.78% | 10.78% | 10.56% | 10.43% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
8.77 | 10.07 | 18.58 | 22.45 | |
Operating CF/Net income |
2.05 | 1.88 | 1.82 | 1.78 | |
Depreciation/Fixed assets |
0.06 | 0.06 | 0.06 | 0.06 | |
Capex/Depreciation |
(3.08) | (2.95) | (2.92) | (2.68) | |
Revenue per Share |
4.92 | 5.10 | 5.22 | 5.29 | |
Operating CF per Share |
1.19 | 1.12 | 1.04 | 1.06 | |
Capex per Share |
(1.13) | (1.16) | (1.17) | (1.09) | |
Capex to Sales |
0.23 | 0.23 | 0.22 | 0.21 |
Columns are period end dates · fundamentals updated 5 Nov 2026